Why Novavax Stock Slipped Thursday

Motley Fool2021-09-10

(Update: Sept 10, 2021 at 04:14 a.m. ET)

Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.

Key Points

  • A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.
  • EUA for the vaccine in India was originally expected in October but will now be pushed back.
  • The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.

What happened

Shares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).

So what

SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.

The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.

This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.

Now what

Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.

Novavax fell over 2% in premarket trading.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • W00dy
    2021-09-11
    W00dy
    Like pls, thanks
  • bernardtayet
    2021-09-11
    bernardtayet
    It is a knee jerk response. The stock holds great potential. Monitor n accumulate. 
  • Deonc
    2021-09-11
    Deonc
    ok
  • FrederickL
    2021-09-11
    FrederickL
    Oh oh…. 
  • lewisleeks
    2021-09-11
    lewisleeks
    [Surprised] [Surprised] 
  • CYKuan
    2021-09-11
    CYKuan
    Novavax is one of the important and safer vaccine with less long term genetic side effect as compared to other mRNA vaccines available. For sure the stock price will rocket when it get approved in the near future in several big country 
发表看法
18